This page lists the SEC filings reported by Eventide Asset Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | 908 Devices Inc. | 1,430,995 | 4.4% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | COLLEGIUM PHARMACEUTICAL, INC | 2,630,478 | 8.1% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Freeline Therapeutics Holdings plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | MARINUS PHARMACEUTICALS, INC. | 4,529,997 | 8.3% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Praxis Precision Medicines, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | VectivBio Holding AG | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Xometry, Inc. | 5,727,770 | 12.6% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Annexon, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Mirum Pharmaceuticals, Inc. | 2,693,581 | 5.8% | EDGAR |
| SC 13G | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Celldex Therapeutics, Inc. | 3,630,013 | 6.6% | EDGAR |
| SC 13G | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Inozyme Pharma, Inc. | 3,179,837 | 5.2% | EDGAR |
| SC 13G | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Korro Bio, Inc. | 546,325 | 6.8% | EDGAR |
| SC 13G/A | 2023-12-11 | EVENTIDE ASSET MANAGEMENT, LLC | Aura Biosciences, Inc. | 5,802,682 | 11.8% | EDGAR |
| SC 13G/A | 2023-12-11 | EVENTIDE ASSET MANAGEMENT, LLC | Zentalis Pharmaceuticals, Inc. | 11,559,975 | 16.3% | EDGAR |
| SC 13G | 2023-12-11 | EVENTIDE ASSET MANAGEMENT, LLC | Lexeo Therapeutics, Inc. | 3,002,831 | 11.9% | EDGAR |
| SC 13G | 2023-11-13 | EVENTIDE ASSET MANAGEMENT, LLC | Xometry, Inc. | 5,730,339 | 12.6% | EDGAR |
| SC 13G | 2023-11-13 | EVENTIDE ASSET MANAGEMENT, LLC | VYNE Therapeutics Inc. | 1,394,336 | 10.0% | EDGAR |
| SC 13G | 2023-10-10 | EVENTIDE ASSET MANAGEMENT, LLC | Zentalis Pharmaceuticals, Inc. | 7,814,039 | 11.1% | EDGAR |
| SC 13G/A | 2023-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | KnowBe4, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Praxis Precision Medicines, Inc. | 3,518,062 | 7.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.